Patients with antiphospholipid syndrome display endothelial perturbation

Journal of Autoimmunity

Volumn 34, Issue 2, 2010, Pages 105-110

  Cugno, Massimo ^b   Borghi, Maria Orietta ^a,b   Lonati, Laura Maria ^a   Ghiadoni, Lorenzo ^c   Gerosa, Maria ^a   Grossi, Claudia ^a   De Angelis, Valentina ^b   Magnaghi, Gaia ^a   Tincani, Angela ^d   Mari, Daniela ^a,b   Riboldi, Piersandro ^a,b   Meroni, Pier Luigi ^a,b  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Adhesion molecules; Anti phospholipid syndrome; Endothelium; Risk factors

Indexed keywords

ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTERY BLOOD FLOW; ARTICLE; ATHEROSCLEROSIS; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; BRACHIAL ARTERY; CAROTID ARTERIES; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; DILATATION, PATHOLOGIC; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 75349108595     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.07.004     Document Type: Article

References (41)

1. Giannakopoulos B., Passam F., Rahgozar S., and Krilis S.A. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 109 (2007) 422-430
2. Pierangeli S.S., Chen P.P., Raschi E., Scurati S., Grossi C., Borghi M.O., et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 34 (2008) 236-250
3. Meroni P.L. Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity. J Autoimmun 30 (2008) 99-103
4. Fischetti F., Durigutto P., Pellis V., Debeus A., Macor P., Bulla R., et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 106 (2005) 2340-2346
5. Shoenfeld Y., Meroni P.L., and Cervera R. Antiphospholipid syndrome dilemmas still to be solved: 2008 status. Ann Rheum Dis 67 (2008) 438-442
6. Kaplanski G., Cacoub P., Farnarier C., Marin V., Gregoire R., Gatel A., et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum 43 (2000) 55-64
7. Williams F.M., Parmar K., Hughes G.R., and Hunt B.J. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost 84 (2000) 742-746
8. Frijns C.J., Derksen R.H., De Groot P.G., Algra A., and Fijnheer R. Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus. Clin Exp Immunol 125 (2001) 149-154
9. Meroni P.L., Borghi M.O., Raschi E., Ventura D., Sarzi Puttini P.C., Atzeni F., et al. Inflammatory response and the endothelium. Thromb Res 114 (2004) 329-334
10. Mercanoglu F., Erdogan D., Oflaz H., Kücükkaya R., Selcukbiricik F., Gül A., et al. Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome. Int J Clin Pract 58 (2004) 1003-1007
11. Stalc M., Poredos P., Peternel P., Tomsic M., Sebestjen M., and Kveder T. Endothelial function is impaired in patients with primary antiphospholipid syndrome. Thromb Res 118 (2005) 455-461
12. Der H., Kerekes G., Veres K., Szodoray P., Toth J., Lakos G., et al. Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus 16 (2007) 497-503
13. Gresele P., Migliacci R., Vedovati M.C., Ruffatti A., Becattini C., Facco M., et al. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res 123 (2009) 444-451
14. Bilora F., Sartori M.T., Zanon E., Campagnolo E., Arzenton M., and Rossato A. Flow-Mediated arterial dilation in primary antiphospholipid syndrome. Angiology 60 (2009) 104-107
15. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006) 295-306
16. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40 (1997) 1725-1734
17. Griffiths B., Mosca M., and Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 19 (2005) 685-708
18. Meroni P.L., Peyvandi F., Foco L., Bernardinelli L., Fetiveau R., Mannucci P.M., et al. on behalf of the atherosclerosis, thrombosis and vascular biology Italian study group. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost 5 (2007) 2421-2428
19. Tripodi A., Mancuso M.E., Chantarangkul V., Clerici M., Bader R., Meroni P.L., et al. Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants. Clin Chem 51 (2005) 1883-1885
20. Fatti L.M., Bottasso B., Invitti C., Coppola R., Cavagnini F., and Mannucci P.M. Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. J Endocrinol Invest 23 (2000) 145-150
21. Cugno M., Agostoni P., Mari D., Meroni P.L., Gregorini L., Bussotti M., et al. Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin-converting enzyme treatment. Relationships with endothelial function, coagulation and inflammation. Br J Haematol 130 (2005) 113-120
22. Erdbruegger U., Haubitz M., and Woywodt A. Circulating endothelial cells: a novel marker of endothelial damage. Clin Chim Acta 373 (2006) 17-26
23. Blann A.D., Woywodt A., Bertolini F., Bull T.M., Buyon J.P., Clancy R.M., et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 93 (2005) 228-235
24. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., et al. International Brachial Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. A report of the International brachial artery reactivity task force. J Am Coll Cardiol 39 (2002) 257-267
25. Ghiadoni L., Magagna A., Versari D., Kardasz I., Huang Y., Taddei S., et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 41 (2003) 1281-1286
26. 2003. ESH/ESC guidelines for the management of arterial hypertension. Guidelines Committee. J Hypertens 21 (2003) 1011-1053
27. De Angelis V., Scurati S., Raschi E., Liutkus A., Belot A., Borghi M.O., et al. Pro-inflammatory genotype as a risk factor for aPL-associated thrombosis: report of a family with multiple anti-phospholipid positive members. J Autoimmun 32 (2009) 60-63
28. Shoenfeld Y., Gerli R., Doria A., Matsuura E., Cerinic M.M., Ronda N., et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112 (2005) 3337-3347
29. Matsuura E., Kobayashi K., Tabuchi M., and Lopez L.R. Accelerated atheroma in the antiphospholipid syndrome. Rheum Dis Clin North Am 32 (2006) 537-551
30. Jimenez S., Garcia-Criado M.A., Tassies D., Reverter J.C., Cervera R., Gilabert M.R., et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 44 (2005) 756-761
31. Ames P.R., Margarita A., Sokoll K.B., Weston M., and Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 64 (2005) 315-317
32. Christodoulou C., Sangle S., and D'Cruz D.P. Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome. Rheumatol (Oxford) 46 (2007) 907-910
33. Belizna C.C., Richard V., Primard E., Kerleau J.M., Cailleux N., Louvel J.P., et al. Early atheroma in primary and secondary antiphospholipid syndrome: an intrinsic finding. Semin Arthritis Rheum 37 (2008) 373-380
34. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 114 (2004) 593-595
35. Asanuma Y., Oeser A., Shintani A.K., Turner E., Olsen N., Fazio S., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Eng J Med 349 (2003) 2047-2115
36. Roman M.J., Shanker B.A., Davis A., Lockshin M.D., Sammaritano L., Simantov R., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349 (2003) 2399-2406
37. Matsushima Y., Takase B., Uehata A., Kawano H., Yano K., Ohsuzu F., et al. Comparative predictive and diagnostic value of flow-mediated vasodilation in the brachial artery and intima media thickness of the carotid artery for assessment of coronary artery disease severity. Int J Cardiol 117 (2007) 165-172
38. Gokce N., Keaney Jr. J.F., Hunter L.M., Watkins M.T., Nedeljkovic Z.S., Menzoian J.O., et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 41 (2003) 1769-1775
39. Yeboah J., Crouse J.R., Hsu F.C., Burke G.L., and Herrington D.M. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 115 (2007) 2390-2397
40. Kiss E., Soltesz P., Der H., Kocsis Z., Tarr T., Bhattoa H., et al. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun 27 (2006) 211-217
41. Korkmaz H., and Onalan O. Evaluation of endothelial dysfunction: flow-mediated dilation. Endothelium 15 (2008) 157-163